The French company, Alizé Pharma 3, has raised €67 million in a Series A financing round to advance two preclinical products for rare endocrine and metabolic diseases into clinical development. The funding round was led by Life Sciences Partners of the Netherlands and included Novo Ventures, Kurma Partners, Orbimed, Pontifax, Partners Innovation Fund and Innobio 2, which is managed by Bpifrance.
The existing shareholders, Sham Innovation Santé/Turenne Capital, Crédit Agricole Création and TAB Consulting also participated in the round.